- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06354413
Outcomes of Concomitant Bypass Surgery in Septal Myectomy
Establishing a Database of Patients Undergoing Surgery for Hypertrophic Cardiomyopathy (Concomitant Bypass Surgery)
Study Overview
Status
Intervention / Treatment
Detailed Description
Surgical septal myectomy (SM) is an effective approach for treating patients with drug-refractory obstructive hypertrophic cardiomyopathy (HCM).However, numerous patients with HCM exhibit concurrent ischemic heart disease, including atherosclerotic coronary artery disease (CAD) and myocardial bridging (MB). Although patients with HCM have been known to possess diminished coronary flow reserve,additional CAD can worsen myocardial ischemia, contributing to an unfavorable prognosis.MB, although infrequent, may affect diastolic heart perfusion, leading to angina and even sudden death.Current guidelines recommend revascularization for ischemic heart disease caused by CAD and MB.However, the impact of concomitant coronary revascularization during HCM management remains unclear. In this study, we analyzed the clinical characteristics and surgical scenarios of patients who underwent concomitant coronary artery bypass grafting (CABG) during ventricular SM and investigated their prognosis.
Patient clinical and survival data from 2009-2020 were retrospectively reviewed. The median follow-up period was 5.1 years. All-cause mortality was the primary endpoint.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Clinical diagnosis of obstructive hypertrophic cardiomyopathy.
- Undergo ventricular septal resection and cardiac bypass surgery at the same time.
Exclusion Criteria:
Incomplete surgical and follow-up data
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
all-cause mortality
Time Frame: through study completion, an average of 5 year
|
death because of any reason
|
through study completion, an average of 5 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cardiac-related deaths and readmission
Time Frame: through study completion, an average of 5 year
|
deaths and readmission because of heart failure, stoke, and etc.
|
through study completion, an average of 5 year
|
Collaborators and Investigators
Investigators
- Study Director: Tao Lu, MD, Fuwai Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Congenital Abnormalities
- Pathological Conditions, Anatomical
- Aortic Valve Disease
- Heart Valve Diseases
- Coronary Disease
- Heart Defects, Congenital
- Cardiovascular Abnormalities
- Aortic Stenosis, Subvalvular
- Aortic Valve Stenosis
- Coronary Vessel Anomalies
- Coronary Artery Disease
- Hypertrophy
- Cardiomyopathies
- Cardiomyopathy, Hypertrophic
- Myocardial Bridging
Other Study ID Numbers
- 2023-2261
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.